PRAME is re-expressed in a wide range of cancers, including melanoma [18,19], renal cell cancer [20], non-small cell lung cancer (NSCLC) [21], neuroblastoma [22], breast cancer [23,24], multiple myeloma [25,26], acute leukemia [27,28], chronic myeloid leukemia [25,29], multiple sarcoma subtypes [30,31], and primary and metastatic uveal melanoma [32,33]. Here, PRAME is linked to cancer.